Devonian Health Group Inc.

GSD

CA2518341078

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 03:01:37 2024-04-23 pm EDT			5-day change	1st Jan Change
0.22 ^CAD	0.00%		0.00%	+51.72%

Mar. 28	Devonian Health Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	CI
Mar. 14	Devonian Health Group Closes Non-Brokered Private Placement; Down Nearly 7%	MT

Devonian Health Group Inc. Reports Earnings Results for the Full Year Ended July 31, 2022

November 28, 2022 at 12:17 pm EST

Devonian Health Group Inc. reported earnings results for the full year ended July 31, 2022. For the full year, the company reported net loss was CAD 3.45 million compared to CAD 3.35 million a year ago.

Latest news about Devonian Health Group Inc.

Devonian Health Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	Mar. 28	CI
Devonian Health Group Closes Non-Brokered Private Placement; Down Nearly 7%	Mar. 14	MT
Devonian Health Group Inc. announced that it has received CAD 0.2238 million in funding	Mar. 12	CI
Devonian Health Group Inc. Appoints Kathryn J. Gregory to the Board	Feb. 29	CI
Devonian Announces $2.16 Million Secured Term Loan Following Repayment of $3.5 Million Long Term Loan	Feb. 26	CI
Devonian Health Group Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	Dec. 22	CI
Devonian Health Group Inc. Announces CEO Changes	Dec. 04	CI
Devonian Health Group Inc. Announces Changes to its Board	Dec. 04	CI
Devonian Health Group Inc. Reports Earnings Results for the Full Year Ended July 31, 2023	Nov. 28	CI
Devonian Health Group Inc. Files Patent Cooperation Treaty Application for Thykamine?? in Wound Healing	Nov. 08	CI
Devonian Health Group Inc. announced that it has received CAD 0.5 million in funding	23-08-31	CI
Devonian Health Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	23-06-28	CI
Devonian Health Group Inc. announced that it has received CAD 1.199665 million in funding	23-06-05	CI
Devonian Health Group Plans to Raise Up To $5 Million via Private Placement	23-05-19	MT
Devonian Health Group Inc. announced that it expects to receive CAD 5 million in funding	23-05-18	CI
Devonian Health Group Announces Presentation of ThykamineTM Efficacy Results in Atopic Dermatitis at the World Congress of Dermatology and Provides ThykamineTM Clinical Development Program Update	23-05-16	CI
Devonian Health Group Announces the Appointment of New Board Members	23-05-12	CI
Devonian Health Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	23-03-24	CI
Devonian Health Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	23-03-24	CI
Devonian Health Group Inc. Announces Executive Appointments	23-03-24	CI
Devonian Health Group Inc. Announces Executive Changes	23-01-06	CI
Devonian Health Group Inc. Reports Earnings Results for the First Quarter Ended October 31, 2022	22-12-22	CI
Devonian Health Group Inc. Reports Earnings Results for the Full Year Ended July 31, 2022	22-11-28	CI
Devonian Health Group Inc. Auditor Raises 'Going Concern' Doubt	22-11-27	CI
Devonian Health Group Inc. to Present ThykamineTM Phase 2 Clinical Results at the 6th Dermatology Drug Development Summit for Inflammatory Skin Diseases	22-10-12	CI

Chart Devonian Health Group Inc.

Duration

Period

More charts

Company Profile

Devonian Health Group Inc. is a Canada-based late-stage botanical pharmaceutical company. The Company's main activity is the development of botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases, including ulcerative colitis and atopic dermatitis. It is also involved in the development of value-added products for dermo-cosmetics and the distribution of pharmaceutical products through its subsidiary. The Companyâs flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The Companyâs flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The Company's cosmeceutical products include R-Spinasome and Purgenesis.

Sector

Pharmaceuticals

Calendar

2024-06-25 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DEVONIAN HEALTH GROUP INC.	+51.72%	23.82M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals